How are current allogenic preparative regimens?

Unpublished evidence suggests myeloablative approaches superior to RIC for AML/MDS Busulfan-based regimens (adult data) Bu/Cy, Bu/Fludarabine, Treosulfan Retrospective evidence suggests TBI-based approaches better for ALL Prospective iBFM trial testing this TBI ≥1200cGy in 6 or 8 fractions + cyclophosphamide, VP-16, or thiotepa Non-malignant disorder prep regimens vary RIC for HLH—flu/melphalan, RIC whenever possible Some disorders require reduced, minimal, or no prep FA—sensitive to TBI, some approaches 300cGy, others low dose chemo SCID—Sib donors, no prep needed, URD, less prep may be possible.